Literature DB >> 19444590

Role of PET/CT in the detection of liver metastases from colorectal cancer.

A Orlacchio1, O Schillaci, N Fusco, P Broccoli, M Maurici, M Yamgoue, R Danieli, S D'Urso, G Simonetti.   

Abstract

PURPOSE: The aim of this study was to compare the diagnostic accuracy of 2-[fluorine-18] fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) and computed tomography (CT) with PET/CT in the detection of liver metastases during tumour staging in patients suffering from colorectal carcinoma for the purposes of correct surgical planning and follow-up.
MATERIALS AND METHODS: A total of 467 patients underwent a PET/CT scan using an iodinated contrast medium. We compared images obtained by the single PET scan, the single CT scan and by the fusion of the two procedures (PET/CT). The final diagnosis was obtained by histological examination and/or by the follow-up of all patients, including those who did not undergo surgery or biopsy.
RESULTS: The PET scan had 94.05% sensitivity, 91.60% specificity and 93.36% accuracy; the CT scan had 91.07% sensitivity, 95.42% specificity and 92.29% accuracy. The combined procedures (PET/CT) had the following values: sensitivity 97.92%, specificity 97.71% and accuracy 97.86%.
CONCLUSIONS: This study indicates that PET/CT is very useful in staging and restaging patients suffering from colorectal cancer. It was particularly useful when recurrences could not be visualised either clinically or by imaging despite increasing tumour markers, as it guaranteed an earlier diagnosis. PET/CT not only provides high diagnostic performance in terms of sensitivity and specificity, enabling modification of patient treatment, but it is also a unique, high-profile procedure that can produce cost savings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444590     DOI: 10.1007/s11547-009-0393-7

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  32 in total

Review 1.  Software for image registration: algorithms, accuracy, efficacy.

Authors:  Brian F Hutton; Michael Braun
Journal:  Semin Nucl Med       Date:  2003-07       Impact factor: 4.446

Review 2.  Positron emission tomography imaging for gynecologic malignancy.

Authors:  Chyong-Huey Lai; Tzu-Chen Yen; Ting-Chang Chang
Journal:  Curr Opin Obstet Gynecol       Date:  2007-02       Impact factor: 1.927

3.  Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.

Authors:  Jong-Ho Kim; Johannes Czernin; Martin S Allen-Auerbach; Benjamin S Halpern; Barbara J Fueger; Joel R Hecht; Osman Ratib; Michael E Phelps; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2005-04       Impact factor: 10.057

4.  PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients.

Authors:  A K Berthelsen; S Holm; A Loft; T L Klausen; F Andersen; L Højgaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-21       Impact factor: 9.236

5.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.

Authors:  H Abdel-Nabi; R J Doerr; D M Lamonica; V R Cronin; P J Galantowicz; G M Carbone; M B Spaulding
Journal:  Radiology       Date:  1998-03       Impact factor: 11.105

7.  Image analysis in patients with cancer studied with a combined PET and CT scanner.

Authors:  M Charron; T Beyer; N N Bohnen; P E Kinahan; M Dachille; J Jerin; R Nutt; C C Meltzer; V Villemagne; D W Townsend
Journal:  Clin Nucl Med       Date:  2000-11       Impact factor: 7.794

Review 8.  Clinical role of FDG PET in evaluation of cancer patients.

Authors:  Lale Kostakoglu; Harry Agress; Stanley J Goldsmith
Journal:  Radiographics       Date:  2003 Mar-Apr       Impact factor: 5.333

Review 9.  Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.

Authors:  Bastiaan Wiering; Theo J M Ruers; Wim J G Oyen
Journal:  Expert Rev Anticancer Ther       Date:  2004-08       Impact factor: 4.512

10.  Patient selection for hepatic resection of colorectal metastases.

Authors:  H J Wanebo; Q D Chu; M P Vezeridis; C Soderberg
Journal:  Arch Surg       Date:  1996-03
View more
  5 in total

1.  Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT.

Authors:  L Bacigalupo; S Aufort; M C Eberlé; E Assenat; M Ychou; B Gallix
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

2.  [Importance of PET/CT for imaging of colorectal cancer].

Authors:  F G Meinel; N Schramm; A R Haug; A Graser; M F Reiser; C Rist
Journal:  Radiologe       Date:  2012-06       Impact factor: 0.635

3.  Role of 18F-FDG PET/CT vs CT-scan in patients with pulmonary metastases previously operated on for colorectal liver metastases.

Authors:  Victor Lopez-Lopez; Ricardo Robles; Roberto Brusadin; Asuncion López Conesa; Juan Torres; Domingo Perez Flores; Jose Luis Navarro; Pedro Jose Gil; Pascual Parrilla
Journal:  Br J Radiol       Date:  2017-10-27       Impact factor: 3.039

4.  Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer.

Authors:  Siva P Raman; Sushanth Reddy; Matthew J Weiss; Lindsey L Manos; John L Cameron; Lei Zheng; Joseph M Herman; Ralph H Hruban; Elliot K Fishman; Christopher L Wolfgang
Journal:  AJR Am J Roentgenol       Date:  2015-01       Impact factor: 3.959

Review 5.  Rectal cancer staging: focus on the prognostic significance of the findings described by high-resolution magnetic resonance imaging.

Authors:  Adriana Dieguez
Journal:  Cancer Imaging       Date:  2013-07-22       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.